Registration - Organization

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Canada Country President

Registration Information

Organization name: Novartis Pharmaceuticals Canada Inc.
Senior Officer Name: Mark Vineis, Canada Country President
Senior Officer Change History
Initial registration start date: 2010-05-04
Registration status: Active
Projected end date: No date provided
Registration number: 10154-2301

Associated Lobbying Activity Reports

Total number of Lobbying Activity Reports: 13

Lobbying Activity Reports - last 6 months: 0

Version 34 of 38 (2023-06-05 to 2023-09-22)

Registration versions:

Version 34 of 38 (2023-06-05 to 2023-09-22)

Lobbying Information

Subject Matter of the Lobbying Activities

Details Regarding the Identified Subject Matter

Will any of the lobbyists listed within this registration arrange a meeting between a public office holder and any other individual for the purpose of attempting to influence any of the matters listed below:

Yes

Specific Topics of Lobbying Communications	Intended Outcomes	Associated Subject Matters
CC on an email message to department staff regarding Health Canada Approval of an important new therapy.	Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health
Deliver a 'pipeline review' presentation to provide Pharmacare program management with details of products currently under development (or not yet available in Canada) for which Pharmaceutical, Laboratory & Blood Services Division (PLBSD) will be making future funding decisions.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals, Senior Citizens
Deliver a 'pipeline review' presentation to provide Pharmacare program management with details of products currently under development (or not yet available in Canada) for which Pharmaceutical Services Division will be making future funding decisions.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals
Discussions with BC government officials/organizations and elected representatives to obtain public reimbursement of Novartis' innovative pharmaceutical treatments for BC citizens that require publicly funded access to these treatments, through various BC government programs such as Pharmacare, Health Authorities, BC Cancer Agency, etc. And, to encourage the BC government to recognize the importance of Novartis investments in Research and Development to the development of BC's healthcare bioscience research ecosystem and to providing innovative approaches to management of the health care system.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals, Science and Technology, Senior Citizens
Discussions with BC government officials/organizations and elected representatives to obtain public reimbursement of Novartis' innovative treatments for BC citizens that require access to these treatments, through various BC government funded programs such as Pharmacare, Health Authorities, BC Cancer Agency, etc. And, to encourage the BC government to recognize the importance of Novartis investments in Research and Development to the development of BC's healthcare bioscience research ecosystem and to providing innovative approaches to management of the health care system.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Economic Development and Trade, Health, Hospitals
Meeting request to explore and understand BC Ministry of Health challenges, barriers, timelines and possible solutions to enable patients to be treated with innovative specialized therapies at sites in BC. (BC patients currently do not have access or are traveling to out-of-province jurisdictions to receive some innovative therapies.)	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health
Meetings with government officials regarding government funding to facilitate patient access to Novartis pharmaceutical treatments	Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health
Meeting with the Minister of Jobs, Economic Development and Innovation to discuss the BC Life Sciences Strategy and Novartis' role as a key partner in the province's bioscience ecosystem, including data partnerships, patient access to innovative medicines and expanded access to diagnostic equipment.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Economic Development and Trade, Health, Science and Technology
Request a meeting to discuss innovative program pioneered by the NHS (England) to address cardiovascular disease risk factor mitigation through a collaborative program created to identify and treat patients high risk for CVD due to elevated cholesterol levels that does not meet current Clinical Guideline standards as published by the Canadian Cardiovascular Congress. Enacting such a program in BC will impact health system resource use caused by the downstream impact of Cardiovascular disease; heart attack, stroke, etc.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity	Health, Hospitals, Senior Citizens

BC Ministries/Provincial Entities

Fraser Health Authority
Health
Innovate BC
Jobs, Economic Development and Innovation
Member(s) of the BC Legislative Assembly
Office of the Premier
Providence Health Care Society
Provincial Health Services Authority
Vancouver Coastal Health Authority
Vancouver Island Health Authority

Organization Details

Senior Officer Name and Position during the Period of this Registration

Andrea Marazzi, Novartis Country President Canada

Organization Contact Information

Novartis Pharmaceuticals Canada Inc.

Address:
700 St-Hubert Street, Suite 100
Montreal, QC H2Y 0C1
Canada

Telephone number: 780-288-1286

Description of Activities

Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative medicines and procedures to improve the health and well-being of Canadians. Novartis is a leading investor in pharmaceutical research and development worldwide and in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 900 people and has been named multiple times as one of the "50 Best Employers in Canada". For further information, please visit www.novartis.ca.

Gifts or benefits provided by the organization

Gifts or Benefits Provided to Public Officer Holders
Name	Gift or Benefit Description	Circumstance	Date Promised	Value Promised	Date Given	Value Given
No Records

Contributors to the Lobbying Activity

No person or organization contributed over $1000CDN, within the preceding 12 months, toward the lobbying activity on behalf of the organization that has a direct interest in the outcome of the lobbying activity.

Government Funding in the Last 12 Months

No government funding was requested or received within the preceding 12 months.

Coalition Members Information

Novartis Pharmaceuticals Canada Inc. is not a coalition member.

Affiliates with a Direct Interest in the Outcome

Novartis Pharmaceuticals Canada Inc. does not have any affiliates that could have a direct interest in the outcome of the lobbying activities

Other Persons or Organizations with Direct Interests

The activities of Novartis Pharmaceuticals Canada Inc. are not controlled or directed by another person or organization with a direct interest in the outcome of this undertaking.

Lobbyists Details

Lobbyists Employed by this Organization

Lobbyist

Contributions

Graham Anderson
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No

Lobbied a member of the Legislative Assembly, including a Minister or Premier, on behalf of this organization on or after 2020-09-21 and before 2024-09-21: No

Caroline Barber
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No